Monday, 18 June 2018 - 4:31
  • it
  • de
  • en
  • fr

Trials

Gilead-Galapagos’ Filgotinib shows efficacy in treating psoriatic arthritis

Gilead Sciences and Belgium-based biotech Galapagos yesterday announced, after Wall Street closed, data from the Phase II EQUATOR trial assessing filgotinib on 131 patients with psoriatic arthritis. The results are positive and demonstrate that filgotinib improves patients’ conditions after as…

Roche’s Tecentriq extends life expectancy of patients with lung cancer (NSCLC)

Switzerland-based Roche some hours ago announced results from the Phase III IMpower130 clinical trial, conducted on patients with non-squamous, non-small cell lung cancer (NSCLC) with Tecentriq (atezolizumab) vs conventional chemotherapy. The trial has shown that Roche’s therapy significantly increases patients’…

Hawaii bans some sunscreens as harmful for coral reefs

The Hawaii Government has passed a bill banning sunscreens containing Oxybenzone and Octinoxate, since these components are lethal for corals in seabed and in reefs. Approximately 6,000 pounds of sunscreen are deposited into the sea and may harm the fragile balance…

Genetics study on hair color origin and meaning

The scientific journal Nature Genetics has published an article reporting the results of a study performed by researchers Pirro G. Hysi and Ana M. Valdes, from King’s College London, on 300,000 people’s DNA, aimed at determining the genetic origins of…

Intercept shows another significant benefit of Ocaliva to people with PCB

New York-based biotech company Intercept Pharmaceuticals keeps momentum: its shares have risen over 15% since the beginning of the month. Intercept yesterday announced in a press release that the Phase III POISE clinical trial has demonstrated that Ocaliva (obeticholic acid)…

New data confirm that adult brain generates new neurons

The scientific journal Cell Stem Cell has published an article contradicting the almost universally shared theory that neurons are generated in the earliest life stages, yet their number does not increase during adulthood. A team of researchers led by scientist…

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

Good Phase III results for Eli Lilly’s Cyramza (liver cancer)

US-based Eli Lilly yesterday announced the results from the Phase III REACH-2 clinical trial, conducted on patients with liver cancer (HCC) treated with Cyramza (ramucirumab) as a second-line treatment. The trial has delivered positive results and investors have soon rewarded…

Good Phase III results for Pfizer’s Tafamidis

Pfizer yesterday night announced that its investigational therapy Tafamidis reduces mortality in patients with a rare heart disease (ATTR-ACT). The statement is supported by positive results from the Phase III ATTR-ACT clinical trial, conducted on 441 patients. According to experts,…

Ups and downs in Germany’s Morphosys’ future

Bavaria-based biotech company Morphosys has published its 2017 financial results, which show that the group’s revenues increased 33% (€67m), yet losses increased as well. However, analysts’ main concern is that Morphosys is expected to be down again at the end…

Dermira’s shares plunge following results from new anti-acne therapy

Shares of California-based Dermira yesterday plunged by 64% (Nasdaq) after results from the Phase III Clareos-1 and Clareos-2 clinical trials were announced. The trials have been conducted on patients with acne vulgaris, treated with the investigational olumacostat glasaretil, which however…

Positive Phase III results for Ipsen’s liver cancer therapy, shares soar

Ipsen and its partner Exelixis have announced they have interrupted the Phase III Celestial clinical trial, since the investigational therapy Cabometyx (cabozantinib) has reached its endpoints earlier than expected. Specifically, Cabometyx has been reported to provide a statistically significant improvement…

Roche granted approval for ocrelizumab (multiple sclerosis) in Europe

Roche has announced that the European Commission has granted a marketing authorization to ocrelizumab, for the treatment of patients with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The European Commission has considered the positive results from the…

CRISPR technology for the treatment of deafness with genetic causes

The journal Nature has published an article reporting a new, significant success of CRISPR technology–Cas9. A team of researchers led by David R. Liu, at Rice University of Houston has succeeded in correcting, using CRISPR technology, a mutant form of…